|本期目录/Table of Contents|

[1]崔家栋,苏迪.降钙素原联合BAP-65评分在慢性阻塞性肺疾病急性加重期患者预后评估中的应用价值[J].慢性病学杂志,2018,(12):1667-1670.
　CUI Jia-dong*,SU Di.Value of procalcitonin combined with BAP-65 score in evaluating the prognosis of patients with acute exacerbation of chronic obstructive pulmonary disease[J].,2018,(12):1667-1670.
点击复制

降钙素原联合BAP-65评分在慢性阻塞性肺疾病急性加重期患者预后评估中的应用价值(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2018年12期
页码:
1667-1670
栏目:
论　著
出版日期:
2018-12-30

文章信息/Info

Title:
Value of procalcitonin combined with BAP-65 score in evaluating the prognosis of patients with acute exacerbation of chronic obstructive pulmonary disease
作者:
崔家栋;  苏迪
东阿县人民医院呼吸内科，山东东阿252201
Author(s):
CUI Jia-dong*;  SU Di
*Department of Respiratory Medicine, Dong’e County People's Hospital, Dong’e Shandong 252201, China Corresponding author: CUI Jiadong, E-mail: 770135085@qq.com
关键词:
慢性阻塞性肺疾病急性加重期; 降钙素原; BAP-65评分; 慢性健康评估评分; 预后
Keywords:
Acute exacerbation of chronic obstructive pulmonary disease;  Procalcitonin;  BAP- 65 score;  Chronic health evaluation Ⅱ score;  Prognosis
分类号:
R563
DOI:
-
摘要:
目的探讨降钙素原（PCT） 联合BAP-65评分对慢性阻塞性肺疾病急性加重期（AECOPD） 患者预后 评估的价值。方法对131 例AECOPD 患者进行回顾性分析，记录入院后24 h 内的血清PCT、BAP-65 评分 和急性生理与慢性健康评估（APACHE） Ⅱ评分。根据预后将患者分为生存组和死亡组、机械通气（MV） 组和 未机械通气（未MV） 组，分析并比较不同组别的上述指标。比较PCT 联合BAP-65 评分与APACHE Ⅱ评分 的曲线下面积（AUROC）。结果死亡组的血清PCT 水平、BAP-65 评分的风险等级、APACHE Ⅱ评分均 高于生存组（均P＜0.01）。与未MV 组比较，MV 组的血清PCT 水平、BAP-65 评分的风险等级、APACHE Ⅱ评分均较高（均P＜0.01）。PCT 联合BAP-65 评分、APACHE Ⅱ评分对AECOPD 患者预测院内死亡率的 AUROC 分别为0.822 和0.839 （P＞0.05），预测机械通气的AUROC 分别为0.756 和0.695 （P＞0.05）。结论 PCT 联合BAP-65评分便捷、有效，可用于评估AECOPD 患者的预后。
Abstract:
Objective To investigate the value of procalcitonin （PCT） combined with BAP- 65 score in prognosis evaluation of patients with acute exacerbation of chronic obstructive pulmonary disease （AECOPD） . Methods A retrospective analysis was performed on 131 cases of patients with AECOPD. The levels of serum PCT, BAP- 65 score, acute physiology and chronic health evaluation （APACHE） Ⅱ score were recorded within 24-hour after admission to hospital. According to the prognosis, the patients were divided into survival group and death group, mechanical ventilation （MV） group and non mechanical ventilation （non-MV） group. The above indicators of different groups were analyzed and compared. The area under the curve （AUROC） of PCT combined with BAP- 65 score and APACHE Ⅱ score （AUROC） was compared among the different groups. Results The levels of serum PCT, BAP- 65 score and APACHE score in the death group were higher than those in the survival group （all P<0.01） . The levels of serum PCT, BAP-65 score and APACHE Ⅱ score were higher in MV group as compared with those in the non-MV group, the differences were statistically significant （all P<0.01） . The AUROC of PCT combined with BAP- 65 score and APACHE Ⅱ score in predicting the mortality of AECOPD patients were 0.822 and 0.839, respectively （P＞0.05） . When predicting the mortality of AECOPD patients by PCT combined with BAP- 65 score and APACHE Ⅱ score in MV group, the AUROC were 0.756 and 0.695, respectively （P＞0.05） .Conclusions PCT combined with BAP-65 score are convenient and practical, which can be used to evaluate the prognosis of patients with AECOPD.

参考文献/References:


[1] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺 疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36 (4):255-264.
[2] Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient- centered outcomes [J]. Chest, 2007, 131(3):696-704.
[3] 降钙素原急诊临床应用专家共识组.降钙素原(PCT)急诊临床应 用的专家共识[J].中华急诊医学杂志,2012,21(9):944-951.
[4] Tabak YP, Sun X, Johannes RS, et al. Mortality and need for mechanical ventilation in acute exacerbations of chronic obstructive pulmonary disease: development and validation of a simple risk score [J]. Arch Intern Med, 2009,169(17): 1595-1602.
[5] Knaus WA, Draper EA, Wagner DP, et al. APACHE Ⅱ: a severity of disease classification system [J]. Crit Care Med, 1985,13(10):818-829.
[6] Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary [J]. Respirol, 2017,22(3):575-601.
[7] 李小莹,肖汉,聂秀红,等. 深吸气量在慢性阻塞性肺疾病急性加 重期治疗效果的评价[J].心肺血管病杂志,2012,31(5):588-590．
[8] Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease [J]. N Engl J Med, 2008,359(22):2355-2365.
[9] 慢性阻塞性肺疾病急性加重抗菌治疗论坛专家组.“慢性阻塞性 肺疾病诊治指南”中急性加重抗菌治疗的地位[J].中华结核和呼 吸杂志,2013,36(9):712-714.
[10] Schuetz P, Christ- Crain M,Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the Pro- HOSP randomized controlled trial [J]. JAMA, 2009,302 (10):1059-1066.
[11] Falsey AR, Becker KL, Swinburne AJ, et al. Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note [J]. Int J Chron Obstruct Pulmon Dis, 2012,7:127-135.
[12] Rammaert B, Verdier N, Cavestri B, et al. Procalcitonin as a prognostic factor in severe acute exacerbation of chronic obstructive pulmonary disease [J]. Respirol, 2009,14 (7):969-974.
[13] Shorr AF, Sun X, Johannes RS, et al. Validation of a novel risk score for severity of illness in acute exacerbations of COPD [J]. Chest, 2011,140(5):1177-1183.
[14] Roche N, Rabbat A, Zureik M, et al. Chronic obstructive pulmonary disease exacerbations in emergency departments: predictors of outcome [J]. Curr Opin Pulm Med, 2010,16 (2):112-117.
[15] 王娱,梁岩,朱俊,等.APACHE-II 和IV 评分系统在心血管危重 症中应用的比较[J].心肺血管病杂志,2014,33(5):662-665.

备注/Memo

备注/Memo:

作者简介：崔家栋，大学本科，副主任医师，研究方向：慢性阻塞性肺疾病和支气管哮喘等病的治疗
通信作者：崔家栋，E-mail: 770135085@qq.com
更新日期/Last Update: 2018-12-30